Related by context. All words. (Click for frequent words.) 68 dose titration 65 PASI scores 65 Dose escalation 65 XEPLION R 65 postintervention 64 dosing cohort 64 Platelet counts 64 tapentadol ER 64 CPAP adherence 63 divalproex sodium 63 dose escalation phase 63 rindopepimut 63 desvenlafaxine succinate 63 neurologic progression 63 dosing interval 63 oral prednisone 62 EDSS score 62 corticosteroid dose 62 mg kg dose 62 evaluable subjects 62 intravitreal injections 62 timepoints 62 certolizumab 62 CIMZIA ™ 62 aromatase inhibitor therapy 62 postprocedure 62 serum phosphate levels 61 quetiapine XR 61 IFN alfa 61 Perforomist Inhalation Solution 61 8mg/kg 61 postoperative chemotherapy 61 oral anticoagulant therapy 61 #mg/m# [002] 61 AGILECT R 61 subcutaneous PRO 61 Androxal TM 61 CIMZIA TM 61 achieving PASI 61 gout flares 60 Zevalin consolidation 60 APTIVUS r 60 urate lowering therapy 60 olanzapine LAI 60 NATRECOR R 60 achieved ACR# 60 RSD# oral 60 relapsed MM 60 methotrexate therapy 60 maximal doses 60 peginterferon 60 corticosteroid therapy 60 ERBITUX therapy 60 IFN α 60 opioid analgesia 60 radiographic progression 60 EDSS scores 60 hour bronchodilation 60 acute mania 60 systemic corticosteroid 60 DLTs 60 PEARL SC 60 virological response 59 prospectively stratified 59 dose cohort 59 telaprevir dosing 59 bolus dose 59 bolus injection 59 DMARD therapy 59 blind placebo 59 mesalamine granules 59 continuous intravenous infusion 59 solifenacin 59 timepoint 59 Postoperative complications 59 secondary efficacy endpoint 59 MIRAPEX ER 59 oral rivaroxaban 59 intermittent dosing 59 intravenous cyclophosphamide 59 label titration 59 venlafaxine XR 59 statin monotherapy 59 MoxDuo TM IR 59 androgen suppression 59 severe exacerbations 59 GLP1 agonist 59 budesonide foam 59 lumbar spine BMD 59 atazanavir ritonavir 59 dopaminergic therapy 59 salmeterol fluticasone 59 STRIDE PD 59 hematologic parameters 59 dosage regimens 59 tipranavir r 59 Hb levels 59 randomisation 59 imatinib therapy 59 Lamictal XR 59 UPDRS scores 59 low dose Iluvien 59 octreotide LAR 59 nadolol 59 INVEGA SUSTENNA 58 oxycodone CR 58 ACTEMRA TM 58 MIRCERA 58 placebo dexamethasone 58 APTIVUS 58 adjuvant tamoxifen therapy 58 symptomatic hypotension 58 efficacy endpoint 58 Primary endpoints 58 INVEGA ® 58 serum clusterin levels 58 paroxysmal AF 58 Hemopurifier ® treatments 58 riociguat 58 QTcF 58 dosing intervals 58 paliperidone ER 58 rotigotine 58 PegIFN RBV 58 recurrent VTE 58 pegaptanib 58 Lucentis injections 58 concomitant AEDs 58 dorzolamide 58 alteplase 58 mg/m2 cohort 58 cilostazol 58 achieved CCyR 58 #mg/m# [001] 58 intravitreal injection 58 PSMA ADC 58 asthma exacerbation 58 rimonabant #mg 58 OPT CHF 58 symptomatic VTE 58 #mg BID [001] 58 Study GL# 58 beta blocker therapy 58 mucosal healing 58 DAPT 58 EDARBI 58 doxorubicin cyclophosphamide 58 RLAI 58 antiandrogen 58 pamidronate 58 crossclamp 58 detectable HCV RNA 58 budesonide formoterol 58 complete cytogenetic response 58 plasma cortisol 58 Ceplene/IL-2 58 foveal thickness 58 serum cortisol 58 #mg doses [002] 58 mg Pycnogenol 58 baminercept 58 GnRH agonist 58 treprostinil 58 mg/m2 dose 58 dose colchicine 58 ratio ICER 58 decitabine 58 placebo controlled clinical 58 COPAXONE R 58 Pharmacokinetic parameters 58 blinded randomized 58 dosing cohorts 58 PRIMO CABG 58 posttreatment 58 levodopa therapy 58 ancrod 58 HbA 1c levels 58 morphometric vertebral fractures 58 infliximab therapy 57 serum phosphate 57 HBeAg seroconversion 57 incontinence episodes 57 serum phosphorous 57 KAPIDEX 57 virological suppression 57 teriflunomide 57 FOLPI 57 electrical cardioversion 57 serum calcium levels 57 intravenous dosing 57 tumor progression TTP 57 MBCT 57 QT QTc 57 eculizumab therapy 57 erosive GERD 57 biochemical relapse 57 AZOR 57 hyperalgesia 57 plus methotrexate 57 multicenter randomized placebo controlled 57 peak plasma concentrations 57 #mg QD [001] 57 OAB symptoms 57 mg/m2/day 57 urinary N telopeptide 57 CR CRu 57 patients evaluable 57 irbesartan 57 active comparator 57 sitaxsentan 57 IFN beta 57 mg kg hr 57 VELCADE melphalan 57 TURBT 57 4mg/kg 57 FOLFOX4 57 REMINYL ® 57 insulin detemir 57 femoral neck fracture 57 TNF antagonist 57 inotropic 57 MACUGEN 57 Kaplan Meier estimate 57 Postoperatively 57 Infusion Reactions Severe 57 ER CHOP 57 retinal thickness 57 poststroke 57 pretreatment baseline 57 doxorubicin docetaxel 57 airway narrowing 57 iniparib BSI 57 lipid lowering therapy 57 Zemplar Capsules 57 Phase IIB 57 IOP lowering 57 nodular partial response 57 antiretroviral naive 57 anagrelide 57 MCyR 57 neurocognitive outcomes 57 CRp 57 ximelagatran 57 concomitant antibiotics 57 postdose 57 atorvastatin #mg 57 IV bolus 57 visilizumab 57 opioid induced bowel dysfunction 57 ARCOXIA 57 rapid virological response 57 MIRAPEX 57 hemoglobin A1c levels 57 aprepitant 57 levodopa carbidopa 57 #mg/day [002] 57 #mg/day [001] 57 clopidogrel therapy 57 adalimumab Humira 57 pyridostigmine 57 ropinirole 57 interferon ribavirin 57 ARCALYST ® 57 hypogonadal men 57 sinus rhythm 57 olmesartan 57 nighttime awakenings 57 CIMZIA TM certolizumab pegol 57 clinically meaningful improvement 57 tacrolimus ointment 57 inhaled iloprost 57 weekly intravenous infusions 57 spontaneous bowel movements 57 Traficet EN 57 NATRECOR ® 57 symptomatic intracranial 57 SIMPADICO 56 nicardipine 56 Diamyd r vaccine 56 antiretroviral regimen 56 hsCRP levels 56 steroid dexamethasone 56 eszopiclone 56 MADRS score 56 ritonavir boosted lopinavir 56 angiographic restenosis 56 Fibrillex TM 56 infliximab 56 HBV DNA levels 56 #mg dose [003] 56 KRAS mutations occur 56 serum urate 56 postoperative morbidity 56 hypokalemia 56 ADVANCE PD 56 SPIRIVA HandiHaler 56 vasogenic edema 56 amoxicillin clavulanate 56 subcutaneous SC 56 EXJADE 56 6MWD 56 CIMZIA R 56 thorough QT 56 tamoxifen therapy 56 mg eq 56 rFSH 56 oral methylnaltrexone 56 androgen blockade 56 vitamin B# folic acid 56 receiving golimumab 56 REMICADE ® 56 intravenous diuretics 56 degarelix 56 goserelin 56 ug kg 56 ARB telmisartan 56 endoscopic remission 56 QALE 56 odanacatib 56 adalimumab 56 postoperative bleeding 56 unboosted 56 BYSTOLIC 56 Teriflunomide 56 NLX P# 56 moderate renal impairment 56 RAPTIVA 56 clomipramine 56 induction regimen 56 #.#/#.# mmHg [001] 56 tolvaptan 56 Cladribine tablets 56 cholinesterase inhibitor 56 Thorough QT 56 double blinded placebo 56 dexmedetomidine 56 virologic response 56 CYPHER Stent 56 CHOP chemotherapy 56 oral olanzapine 56 analgesic medications 56 HAQ DI 56 calcineurin inhibitor 56 serum sodium levels 56 abatacept 56 golimumab CNTO 56 AGILECT ® 56 undetectable HBV DNA 56 ginkgo extract 56 mg QD 56 calculated creatinine clearance 56 CCyR 56 DCCT 56 fibrinolytic therapy 56 weekly subcutaneous injections 56 rapid virologic response 56 atrioventricular block 56 postoperative analgesia 56 MVax 56 CD# upregulation 56 genotypic resistance 56 FROVA 56 oxcarbazepine 56 dose Iluvien 56 postoperative mortality 56 IR prednisone 56 mesilate 56 pyrazinamide 56 adjunctive placebo 56 label dose titration 56 clinically meaningful improvements 56 piperacillin tazobactam 56 idraparinux 56 alemtuzumab treated 56 docetaxel chemotherapy 56 mcg kg 56 PANSS scores 56 Hb A1C 56 Bifeprunox 56 subcutaneous enoxaparin 56 lamotrigine 56 lymphocytosis 56 IMPACT DCM 56 definite stent thrombosis 56 iniparib 56 perioperative morbidity 56 MS relapses 56 LEXIVA r 56 rufinamide 56 oral prednisolone 56 mL/min/#.# m 2 56 partial remissions 56 thromboprophylaxis 56 anticoagulation therapy 56 Aloxi injection 56 PRIMO CABG2 56 fibrinolysis 55 haematologic 55 bisphosphonate therapy 55 peg IFN 55 GnRH agonists 55 elective PCI 55 chronic GVHD 55 lesinurad 55 disease progression TTP 55 PSVT 55 oral corticosteroids 55 antiepileptic medications 55 VAPRISOL 55 CLA supplementation 55 preoperative chemotherapy 55 ACTIVE W 55 ZALBIN dosed 55 Severity Index PASI 55 mcg dose 55 dose regimens 55 intravenous bisphosphonates 55 radioiodine therapy 55 Phe restricted diet 55 liver biopsies 55 LNG IUS 55 VcMP 55 CR nPR 55 PULMICORT RESPULES 55 hepatic enzyme 55 Zemiva imaging 55 neutrophil counts 55 subcutaneous infusion 55 pramipexole 55 PCWP 55 CTEPH 55 mitoxantrone plus 55 alicaforsen enema 55 Phase #b/#a 55 R0 resection 55 ULORIC 55 ibandronate 55 phase Ib 55 lymphopenia 55 antihypertensive therapy 55 QTc prolongation 55 tenecteplase 55 inert placebo 55 serum testosterone 55 mITT population 55 oral corticosteroid 55 ICS LABA combination 55 antidepressant efficacy 55 mg BID 55 PEGINTRON TM 55 midstage trials 55 CANCIDAS 55 preintervention 55 PRADAXA 55 cytogenetic response 55 suppressive therapy 55 oxymorphone ER 55 mcg albinterferon alfa 2b 55 antiplatelet medication 55 IMPACT DCM clinical 55 Index CDAI 55 extubation 55 ziconotide 55 hemodynamic instability 55 LIALDA 55 femoral shaft fracture 55 vasospasm 55 CorVue ™ 55 thrombocytopenic patients 55 FOSRENOL ® 55 timolol 55 CDAI 55 idiopathic Parkinson disease 55 FFNS 55 glycoprotein IIb IIIa inhibitor 55 pharmacodynamics PD 55 chemoradiation therapy 55 pivotal bioequivalence 55 Lucentis monotherapy 55 inhaled budesonide 55 VFEND 55 divalproex 55 SCIg 55 glycated hemoglobin levels 55 relapsed AML 55 low dose cytarabine 55 Dextofisopam 55 aripiprazole 55 coadministration 55 guanfacine extended release 55 ALT flares 55 eosinophilic asthma 55 hepatic metastases 55 cystoscopic 55 rosuvastatin #mg 55 remission CR 55 plasma HCV RNA 55 tolterodine 55 androgen ablation 55 dosing frequency 55 mg simvastatin 55 systolic function 55 HAART regimens 55 administered subcutaneously 55 VIIBRYD 55 splenectomized patients 55 aldosterone antagonist 55 BENICAR HCT 55 phase IIb trial 55 dose proportionality 55 methotrexate monotherapy 55 midstage clinical 55 warfarin therapy 55 cART 55 macroalbuminuria 55 demonstrated clinically meaningful 55 phase IIa 55 hematologic toxicity 55 dexamethasone Decadron 55 adenotonsillectomy 55 oral antidiabetes 55 lipid lowering medication 55 mcg QD 55 underwent liver transplantation 55 mcg BID 55 MAGE A3 ASCI 55 plus MTX 55 moderately emetogenic 55 paliperidone palmitate 55 LATUDA 55 serum potassium levels 55 PRADAXA #mg 55 Elitek 55 paricalcitol 55 cerebral angiography 55 prodromal symptoms 55 oral FTY# 55 brivaracetam 55 cerebrovascular events 55 methacholine challenge 55 plasma pharmacokinetics 55 pulmonary exacerbation 55 plasma uric acid 55 hypofractionated radiation 55 Viread Emtriva 55 COPD exacerbation 55 peg interferon 55 CsA 55 inhaled corticosteroid therapy 55 cannabinor 55 KRAS mutant tumors 55 peginterferon alfa 2a 55 dopamine partial agonist 55 β blockers 55 Peg riba 55 hematological toxicity 55 GENASIS trial 55 Triapine R 55 treatment naive genotype 55 L PPDS 55 UPDRS motor 55 paclitaxel chemotherapy 55 Telintra 55 Febrile neutropenia 55 etanercept 55 SSRI SNRI 55 tiotropium 55 lacosamide 55 Hypotension 55 placebo controlled studies 55 undetectable viral 55 ascending dose 55 intravenous iv 54 COPD exacerbations 54 cytoreduction 54 virologic failure 54 postoperatively 54 comparator arm 54 cisplatin chemotherapy 54 HbA1C levels 54 serum HBV DNA 54 PSA nadir 54 abacavir lamivudine 54 coronary revascularization 54 safinamide 54 Durezol 54 angiographic outcomes 54 UPDRS 54 nortriptyline 54 ziprasidone 54 Lofexidine 54 paclitaxel Taxol R 54 NNT = 54 CLARITY study 54 interferon therapy 54 intradermal injections 54 imipenem 54 Brief Psychiatric 54 randomized Phase 2b 54 immunomodulatory therapy 54 systemic hypotension 54 dose cohorts 54 CDAI score 54 hypoperfusion 54 nephrotoxic drugs 54 galiximab 54 albumin excretion 54 conjunctival hyperemia 54 glomerular filtration 54 Phase 1a 54 antithrombotic therapy 54 cerebral ischemia 54 antiretroviral naïve 54 efalizumab 54 F FDG PET 54 COPAXONE ® 54 amenorrhoea 54 concurrent chemoradiation 54 esomeprazole 54 undetectable HCV RNA 54 PROLACRIA 54 postoperative complication 54 FAMPYRA 54 Betaferon ® 54 placebo controlled Phase 54 standard chemotherapy regimen 54 detrusor overactivity 54 median PFS 54 Psoriasis Area 54 NIHSS score 54 JunJing II 54 dexanabinol 54 Talotrexin 54 nitrofurantoin 54 pegylated interferon alfa 2b 54 Hydroxyurea 54 E1 INT TM 54 Kaplan Meier analysis 54 lanthanum carbonate 54 attain statistical significance 54 intravenous methylnaltrexone 54 montelukast 54 generalized seizures 54 HUMIRA adalimumab 54 daily subcutaneous injections 54 mitoxantrone 54 hypomanic episodes 54 intravenous morphine 54 invasive aspergillosis 54 tocilizumab 54 stellate ganglion block 54 Vimpat R 54 Pegasys plus Copegus 54 symptomatic aortic stenosis 54 elotuzumab 54 pharmacokinetic characteristics 54 GAMMAGARD 54 TORISEL 54 eplerenone 54 cecal intubation 54 QTc interval 54 galantamine 54 histrelin 54 Cimzia TM 54 BRIM3 54 #mg q8h 54 biliary tract cancer 54 somatostatin analog 54 Aptivus ® 54 subcutaneous ORENCIA 54 recombinant PSMA vaccine 54 receiving VICTRELIS 54 eptifibatide 54 nalbuphine ER 54 blinded randomized placebo controlled 54 unresectable HCC 54 senicapoc 54 5FU 54 LHRH agonists 54 nonmetastatic prostate cancer 54 O PPDS 54 ATACAND 54 MEND CABG 54 arterial thromboembolic events 54 sUA 54 cinacalcet 54 ribavirin RBV 54 Arikace 54 phase IIb study 54 IV bisphosphonates 54 azacitidine 54 reperfusion therapy 54 intravenous tPA 54 placebo controlled Phase III 54 cytogenetic responses 54 #mg QD [002] 54 rhTSH 54 dose dose escalation 54 dalteparin 54 polysomnography PSG 54 non menstrual pelvic 54 chlorambucil 54 Phase Ib clinical 54 achieved statistical significance 54 bezafibrate 54 flutamide 54 trial evaluating Prochymal 54 RRMS patients 54 ejaculatory function 54 cortical stimulation 54 sub maximal 54 Dacogen injection 54 modified REGENESIS Phase IIb 54 antiarrhythmic drug 54 PEGPH# 54 venlafaxine ER 54 periprocedural 54 VADT 54 ® escitalopram oxalate 54 MGd 54 BEACOPP 54 coagulation parameters 54 lenalidomide dexamethasone 54 gastroduodenal 54 non hematological toxicities 54 Lupuzor ™ 54 elevated ALT 54 lymph node dissection 54 hypersensitivity allergic reactions 54 methylprednisolone 54 pegylated liposomal doxorubicin 54 PDP MLR 54 Gabapentin GR 54 LHRH agonist 54 p = NS 54 myocardial revascularization 54 anakinra 54 progression TTP 54 prospectively defined 54 HbA 1c 54 epigastric pain 54 NAbs 54 immunosuppressive medication 54 estramustine 54 ZOMIG Nasal Spray 54 HDRS 54 HSCT 54 ispinesib administered 54 adenoma recurrence 54 nadroparin 54 selegiline 54 PROMACTA 54 #mg dose [001] 54 anterior uveitis 54 Halotron revenues 54 phase IIb clinical 54 NYHA functional class 54 randomized multicenter Phase III 54 symptom exacerbation 54 acute gout flares 54 im peramivir 54 erosive esophagitis 54 rituximab Rituxan ® 54 glycosylated hemoglobin HbA1c 54 sleep onset WASO 54 recanalization 54 Major Depressive Disorder MDD 54 ENGAGE AF TIMI 54 placebo controlled randomized 54 eprodisate Fibrillex TM 54 isoproterenol 54 arterial insufficiency 54 trastuzumab Herceptin ® 54 walk distance 6MWD 54 colectomy 53 antiepileptic drugs AEDs 53 Timed Walk 53 REVIVE Diabetes 53 ABVD 53 chronic idiopathic thrombocytopenic purpura 53 daytime somnolence 53 carotid revascularization 53 MIST II 53 MEVACOR 53 Raptiva r 53 cis retinoic acid 53 exogenous insulin 53 azoospermia 53 opioid bowel dysfunction 53 ACZ# 53 sUA levels 53 alvimopan 53 triamcinolone 53 hypomagnesemia 53 Secondary efficacy endpoints 53 dose proportional pharmacokinetics 53 acromegalic patients 53 events AEs 53 subthreshold depression 53 COMBIVIR 53 REVIVE TA 53 chemoradiotherapy 53 octreotide 53 Capesaris 53 ABSORB trial 53 Adjuvant chemotherapy 53 intravenous vancomycin 53 verum acupuncture 53 posttransplant 53 curative resection 53 BeneFIX 53 IIa trial 53 dose escalation 53 OADs 53 adrenal function 53 tolterodine ER 53 μg kg 53 adjuvant tamoxifen 53 MMSE score 53 nonobstructive CAD 53 Phase III randomized controlled 53 mg q8h 53 mycophenolate mofetil 53 LANTUS R 53 pCR 53 HAART regimen 53 inhaled treprostinil 53 antiandrogens 53 randomized #:#:# 53 AVODART 53 dosage regimen 53 Operative mortality 53 clopidogrel pretreatment 53 lung metastases 53 PREZISTA r 53 Unified Parkinson Disease 53 menstrual bleeding 53 A1c levels 53 β blocker 53 FOLFIRI 53 androgen deprivation 53 icatibant 53 Secondary endpoints 53 serum HCV RNA 53 PSADT 53 nitazoxanide 53 intravenous CK # 53 Tasimelteon 53 aspartate aminotransferase AST 53 FOLPI regimen 53 gastrointestinal toxicities 53 total thyroidectomy 53 Certolizumab pegol 53 INCB# [001] 53 intra articular injection 53 GLP toxicology studies 53 ritonavir boosting 53 venous thromboembolic disease 53 prior chemotherapy regimens 53 paroxysmal atrial fibrillation 53 sustained ventricular tachycardia 53 Torisel 53 ABILIFY Injection 53 aldosterone antagonists 53 Peg IFN 53 #mg ATC 53 prazosin 53 dyspnoea 53 cardiac toxicity 53 vernakalant hydrochloride 53 Secondary endpoints include 53 ritonavir boosted 53 mL kg 53 perioperative mortality 53 WBPA 53 metastatic lung cancer 53 rFVIIa 53 citalopram 53 aplindore 53 pneumonectomy 53 brachial artery flow 53 DAS# CRP 53 antidepressant therapy 53 ONTAK 53 darunavir ritonavir 53 adrenalectomy 53 PRECISE Trial 53 TEMSO 53 hepatic enzymes 53 initiate multicenter 53 EBRT 53 microbiologically evaluable 53 oral anticoagulation 53 proximal DVT 53 Bezielle 53 Pemetrexed 53 posaconazole 53 TASKi3 53 laxation 53 tramiprosate Alzhemed TM 53 induce remission 53 canakinumab 53 mycophenolate mofetil MMF 53 secondary efficacy endpoints 53 overnight polysomnography 53 fatigue asthenia 53 measurable tumor regressions 53 tegaserod 53 Betaferon R 53 inhaled tobramycin 53 tipranavir 53 HF ACTION 53 serum urate levels 53 guanfacine 53 nasal symptom 53 liver histology 53 tumor regressions 53 confirmatory clinical 53 Intravail R 53 relapsed APL 53 Status epilepticus 53 subcutaneous dose 53 SERCA2a 53 adriamycin 53 ALND 53 NovoSeven ® 53 deferiprone 53 postop 53 Decitabine 53 aneurysmal subarachnoid hemorrhage 53 periodically reassessed 53 diarrhea dyspepsia 53 Subgroup analyzes 53 tumor resection 53 forodesine 53 transaminases 53 ERBITUX infusion 53 UPPP 53 underwent resection 53 pregabalin 53 pouchitis 53 pulmonary dysfunction 53 renal cysts 53 Cipralex ® 53 asymptomatic hyperuricemia 53 indiplon capsules 53 dose cyclophosphamide 53 renal transplants 53 mg clopidogrel 53 colorectal adenoma 53 bowel resection 53 antibiotic regimens 53 thrombocytopenic 53 BENICAR 53 DETROL LA 53 Keppra ® injection 53 sargramostim 53 intravenous IV infusion 53 adult chronic ITP 53 protease inhibitor PI 53 Phase IIa trials 53 exploratory endpoints 53 inotropes 53 glycated hemoglobin HbA1c 53 heavily pretreated patients 53 annualized relapse 53 Sandostatin LAR 53 virologic 53 Phase 2a trial 53 virologic breakthrough 53 anthracycline chemotherapy 53 huN# DM1 53 ipsilateral stroke 53 immune thrombocytopenic purpura ITP 53 severe neutropenia 53 Serious adverse reactions 53 intraocular pressure IOP 53 KADIAN ® 53 Free Survival PFS 53 Stent thrombosis 53 ACE inhibitor ramipril 53 vismodegib 53 GP IIb IIIa inhibitor 53 nab paclitaxel 53 conjugated equine estrogen 53 fluticasone salmeterol 53 pulmonary exacerbations 53 systemic corticosteroids 53 EXPAREL 53 platelet inhibition 53 TNF alpha inhibitor 53 TPV r 53 titrated glipizide 53 HUMIRA achieved PASI 53 Oral corticosteroids 53 acute postoperative 53 certolizumab pegol 53 briakinumab 53 ocular inflammation